Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

KURA

Kura Oncology Inc

Dec 12 • 04:00PM ET

9.69

Dollar change -0.51
Percentage change -5.00	%

Healthcare • Biotechnology • USA • NASD

Peers: AGIO BLUE FATE ADAP EXEL IOVA KPTI FGEN

| Held by: VTI IWM VXF XBI IWO VTWO IBB SCHA VHT DFAS

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.36	Insider Own	16.10%	Shs Outstand	77.75M	Perf Week	-9.52%
Market Cap	753.53M	Forward P/E	-	EPS next Y	-2.07	Insider Trans	-0.00%	Shs Float	65.25M	Perf Month	-47.82%
Income	-197.55M	PEG	-	EPS next Q	-0.57	Inst Own	97.52%	Short Float	11.20%	Perf Quarter	-53.59%
Sales	0.00M	P/S	-	EPS this Y	-14.67%	Inst Trans	3.57%	Short Ratio	5.67	Perf Half Y	-55.08%
Book/sh	5.45	P/B	1.78	EPS next Y	13.38%	ROA	-41.48%	Short Interest	7.31M	Perf Year	-12.94%
Cash/sh	5.85	P/C	1.66	EPS next 5Y	19.93%	ROE	-46.28%	52W Range	9.68 - 24.17	Perf YTD	-32.61%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-3.94%	ROI	-45.21%	52W High	-59.91%	Beta	0.76
Dividend TTM	-	Quick Ratio	11.47	Sales past 5Y	0.00%	Gross Margin	-	52W Low	0.10%	ATR (14)	0.82
Dividend Ex-Date	-	Current Ratio	11.47	EPS Y/Y TTM	-16.69%	Oper. Margin	-	RSI (14)	21.20	Volatility	5.38% 6.82%
Employees	142	Debt/Eq	0.04	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.31	Target Price	28.57
Option/Short	Yes / Yes	LT Debt/Eq	0.03	EPS Q/Q	-25.19%	Payout	-	Rel Volume	1.39	Prev Close	10.20
Sales Surprise	-	EPS Surprise	-0.62%	Sales Q/Q	-	Earnings	Nov 07 AMC	Avg Volume	1.29M	Price	9.69
SMA20	-19.42%	SMA50	-37.41%	SMA200	-49.80%	Trades		Volume	1,792,450	Change	-5.00%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-24-24	Initiated	UBS	Buy	$27
Oct-14-24	Downgrade	Stifel	Buy → Hold	$26 → $19
Dec-22-23	Initiated	Mizuho	Buy	$26
Aug-11-23	Initiated	BofA Securities	Buy	$31
Jul-27-23	Initiated	Scotiabank	Sector Perform	$10.50
May-17-23	Initiated	BTIG Research	Buy	$31
Jan-31-23	Initiated	Stifel	Buy	$25
Jul-12-22	Initiated	Cantor Fitzgerald	Overweight	$30
Feb-15-22	Initiated	Jefferies	Buy	$35
May-05-21	Resumed	Credit Suisse	Outperform	$42
Apr-26-21	Resumed	Credit Suisse	Outperform	$42
Dec-07-20	Reiterated	H.C. Wainwright	Buy	$40 → $45
Dec-03-20	Initiated	Stifel	Buy	$45
Nov-05-20	Downgrade	Piper Sandler	Overweight → Neutral
Jul-07-20	Initiated	Credit Suisse	Outperform	$27
May-05-20	Initiated	Barclays	Overweight	$24
Jul-18-19	Initiated	Deutsche Bank	Buy	$28
Nov-09-18	Initiated	Piper Jaffray	Overweight
Aug-01-18	Initiated	H.C. Wainwright	Buy	$31
Oct-13-16	Resumed	Leerink Partners	Outperform	$15

Show Previous Ratings

Dec-09-24 07:00AM	Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting (GlobeNewswire)
Dec-04-24 01:25PM	Why Is Kura Oncology, Inc. (KURA) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? (Insider Monkey)
Dec-02-24 07:30AM	Kura Oncology to Host Virtual Investor Event on December 9, 2024 (GlobeNewswire)
Nov-25-24 07:30AM	Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit (GlobeNewswire)
Nov-23-24 10:42AM	Kura Oncology, Inc. (KURA): Among the Most Promising Cancer Stocks According to Hedge Funds (Insider Monkey)
05:30AM	Loading…
Nov-22-24 05:30AM	Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial (BioPharma Dive) +7.36%
Nov-21-24 04:15PM	Kura Crashes 37% After $1.53 Billion Deal Slams The Door On A Takeover (Investor's Business Daily) -36.77%
09:05AM	Kura Oncology Slams The Door On Its Takeover Narrative, And Shares Collapse 26% (Investor's Business Daily)
06:37AM	Kura Oncology partners Kyowa Kirin to advance AML treatment (Pharmaceutical Technology)
Nov-20-24 05:00PM	Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias (PR Newswire)
Nov-08-24 04:01PM	Kura Oncology Inc (KURA) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising Expenses (GuruFocus.com)
Nov-07-24 05:15PM	Kura Oncology: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Kura Oncology Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-05-24 09:09AM	Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting (GlobeNewswire)
Oct-31-24 07:30AM	Kura Oncology to Report Third Quarter 2024 Financial Results (GlobeNewswire)
08:00AM	Loading…
Oct-29-24 08:00AM	Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors (Business Wire)
Oct-24-24 07:30AM	Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST) (GlobeNewswire)
Oct-23-24 07:30AM	Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors (GlobeNewswire)
Oct-09-24 05:54PM	Kura Oncology Inc (KURA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs (GuruFocus.com)
Sep-30-24 06:30PM	Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology (GlobeNewswire)
Sep-17-24 07:30AM	Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors (GlobeNewswire)
Sep-10-24 07:30AM	Kura Oncology to Participate in Cantor Global Healthcare Conference (GlobeNewswire)
Sep-05-24 12:01AM	Kura Oncology, Inc. (KURA): This Small-Cap Healthcare Stock Is A Good Buy Right Now (Insider Monkey)
Sep-02-24 05:22PM	10 Best Small-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-08-24 04:44PM	Kura Oncology: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Kura Oncology Reports Second Quarter 2024 Financial Results (GlobeNewswire)
07:30AM	Kura Oncology Announces FDA Clearance of IND Application for Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors (GIST) (GlobeNewswire)
Aug-01-24 07:30AM	Kura Oncology to Report Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-05-24 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-24-24 07:30AM	Kura Oncology Reports Preclinical Data Supporting Potential for Menin Inhibitor in Diabetes (GlobeNewswire)
09:00AM	Loading…
Jun-17-24 09:00AM	Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies (GlobeNewswire)
Jun-07-24 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-29-24 07:30AM	Kura Oncology to Participate in Jefferies Global Healthcare Conference (GlobeNewswire)
May-14-24 11:44AM	Kura Oncology Enrolls 85 Patients in Ziftomenib Trial for Leukemia Drug (MT Newswires)
07:30AM	Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML (GlobeNewswire)
May-08-24 08:30AM	2 Incredible Growth Stocks to Buy Hand Over Fist (Motley Fool)
07:30AM	Kura Oncology to Participate in Bank of America Securities Healthcare Conference (GlobeNewswire)
May-06-24 10:14AM	Kura Oncology, Inc. (NASDAQ:KURA) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-03-24 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:03AM	Kura Oncology Inc (KURA) (Q1 2024) Earnings Call Transcript Highlights: Key Financial and ... (GuruFocus.com)
May-02-24 08:58PM	KURA Stock Earnings: Kura Oncology Misses EPS for Q1 2024 (InvestorPlace)
04:48PM	Kura Oncology: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Kura Oncology Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-25-24 07:30AM	Kura Oncology to Report First Quarter 2024 Financial Results (GlobeNewswire)
Apr-22-24 07:30AM	Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML (GlobeNewswire)
Apr-10-24 07:30AM	Kura Oncology to Participate in Stifel Targeted Oncology Forum (GlobeNewswire)
Apr-05-24 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-06-24 07:30AM	Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma (GlobeNewswire) +7.89%
Mar-01-24 05:00PM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-28-24 09:56AM	Kura Oncology, Inc. (NASDAQ:KURA) Q4 2023 Earnings Call Transcript (Insider Monkey)
06:56AM	Q4 2023 Kura Oncology Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-27-24 04:44PM	Kura Oncology Inc (KURA) Reports Q4 and Full Year 2023 Financial Results (GuruFocus.com)
04:10PM	Kura Oncology: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-26-24 07:30AM	Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia (GlobeNewswire)
Feb-22-24 07:30AM	Kura Oncology to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Feb-20-24 07:30AM	Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-02-24 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-01-24 03:01PM	Chief Medical Officer Stephen Dale Sells Shares of Kura Oncology Inc (GuruFocus.com)
Jan-30-24 04:07PM	Kura Makes Good On Its $150 Million Infusion And Shoots Up 12% (Investor's Business Daily) +12.10%
07:00AM	Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia (GlobeNewswire)
Jan-24-24 04:22PM	Kura Oncology Rockets 46% Before Unveiling Cancer Drug Test Results Here's Why (Investor's Business Daily) +46.13%
01:16PM	Why Is Cancer Focused Kura Oncology Stock Is Trading Higher Today? (Benzinga)
07:00AM	Kura Oncology Announces Oversubscribed $150 Million Private Placement (GlobeNewswire)
Dec-08-23 07:30AM	Kura Oncology's Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society's Pediatric Acute Leukemia (PedAL) Master Clinical Trial (GlobeNewswire)
Nov-28-23 07:30AM	Kura Oncology to Participate in the JMP Securities Hematology and Oncology Summit (GlobeNewswire)
Nov-05-23 03:44PM	Kura Oncology, Inc. (NASDAQ:KURA) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-02-23 06:46PM	Kura Oncology Inc (KURA) Reports Q3 2023 Financial Results (GuruFocus.com) +5.38% +7.01%
04:36PM	Kura Oncology: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Kura Oncology Reports Third Quarter 2023 Financial Results (GlobeNewswire)
07:30AM	Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRAS -Mutated NSCLC (GlobeNewswire)
Oct-30-23 07:30AM	Kura Oncology to Participate in Three Upcoming Investor Conferences (GlobeNewswire) +6.40%
Oct-26-23 04:05PM	Kura Oncology to Report Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-19-23 07:30AM	Kura Oncology Announces First Patient Dosed in FIT-001 Trial of Next-Generation Farnesyl Transferase Inhibitor KO-2806 (GlobeNewswire)
Oct-17-23 04:05PM	Kura Oncology Announces Positive Results from Registration-Directed Study of Tipifarnib in Patients with HRAS Mutant HNSCC (GlobeNewswire)
Oct-09-23 02:03AM	14 Best Cancer Stocks To Buy Now (Insider Monkey)
Oct-04-23 12:00PM	What Makes Kura Oncology (KURA) a New Buy Stock (Zacks)
07:30AM	Kura Oncology Announces Three Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Sep-28-23 07:30AM	Kura Oncology Reports Preclinical Data Showing Ability of KO-2806 to Enhance Antitumor Activity of KRAS Inhibitors in Non-Small Cell Lung Cancer (GlobeNewswire)
Sep-19-23 07:30AM	Kura Oncology to Participate in Cantor Global Healthcare Conference 2023 (GlobeNewswire)
Aug-14-23 07:30AM	Kura Oncology Appoints Brian Powl as Chief Commercial Officer (GlobeNewswire)
Aug-03-23 04:38PM	Kura Oncology: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Kura Oncology Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-27-23 07:30AM	Kura Oncology to Report Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-11-23 09:35AM	Kura Oncology (KURA) Loses -22.98% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Jun-14-23 07:00AM	Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -9.83%
Jun-13-23 04:01PM	Kura Oncology Announces Commencement of Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Jun-11-23 03:45AM	Kura Oncology Presents Late-Breaking Clinical Data for Menin Inhibitor Ziftomenib at 2023 European Hematology Association (EHA) Congress (GlobeNewswire)
Jun-05-23 08:02PM	Over 100% Upside: Analysts See an Appealing Entry Point in These 2 Small-Cap Stocks (TipRanks)
May-30-23 07:30AM	Kura Oncology Announces Late-Breaking Abstract Accepted for Oral Presentation at the 2023 European Hematology Association (EHA) Congress (GlobeNewswire)
May-23-23 07:30AM	Kura Oncology to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
May-13-23 11:51AM	Kura Oncology, Inc. (NASDAQ:KURA) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-11-23 09:35AM	Q1 2023 Kura Oncology Inc Earnings Call (Thomson Reuters StreetEvents) +8.30%
May-10-23 04:17PM	Kura Oncology: Q1 Earnings Snapshot (AP Finance)
04:03PM	Kura Oncology Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-09-23 07:30AM	Kura Oncology to Participate in JMP Securities Life Sciences Conference (GlobeNewswire)
May-03-23 07:30AM	Kura Oncology to Report First Quarter 2023 Financial Results (GlobeNewswire)
May-01-23 02:07PM	3 Under-the-Radar Stocks That AI Predicts Will Soar in May (InvestorPlace) +7.19%
Apr-18-23 07:30AM	Kura Oncology to Participate in Stifel Targeted Oncology Days (GlobeNewswire)
Apr-17-23 07:30AM	Kura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Farnesyl Transferase Inhibitor in Combination with Targeted Therapies (GlobeNewswire)

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
FORD KATHLEEN	Chief Operating Officer	Nov 18 '24	Sale	16.03	526	8,434	23,184	Nov 19 04:05 PM
FORD KATHLEEN	Officer	Nov 18 '24	Proposed Sale	15.99	526	8,410		Nov 18 04:03 PM
Bair Teresa Brophy	Chief Legal Officer	May 20 '24	Sale	22.15	2,615	57,916	68,979	May 20 06:30 PM
DOYLE THOMAS JAMES	SVP, Finance & Accounting	Jan 29 '24	Sale	17.80	2,318	41,262	48,093	Jan 31 05:30 PM
Bair Teresa Brophy	Chief Legal Officer	Jan 29 '24	Sale	17.80	2,053	36,544	68,979	Jan 31 05:30 PM
FORD KATHLEEN	Chief Operating Officer	Jan 29 '24	Sale	17.80	1,496	26,630	21,602	Jan 31 05:30 PM
DALE STEPHEN	Chief Medical Officer	Jan 29 '24	Sale	17.80	7,158	127,416	43,642	Jan 31 05:30 PM
DALE STEPHEN	Chief Medical Officer	Jan 30 '24	Sale	21.55	4,825	103,980	38,817	Jan 31 05:30 PM
WILSON TROY EDWARD	President and CEO	Jan 24 '24	Option Exercise	6.05	91,052	550,594	84,666	Jan 26 05:10 PM
WILSON TROY EDWARD	President and CEO	Jan 24 '24	Sale	20.23	91,052	1,841,982	559	Jan 26 05:10 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KURA

Kura Oncology Inc

Upgrade your FINVIZ experience